The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Guaranteeing treatment adherence for a number of myeloma therapy entails each sensible techniques and a patient-centered mindset. Care companions spotlight {that a}...
Dr. Justin Gainor, director of the Middle for Thoracic Cancers Program at Massachusetts Common Hospital, shared steering for sufferers with lung most...
